{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
atropine
to a specific field?
Status:
Possibly Marketed Outside US
Source:
Sultroponium-B by Biotherax [France]
Source URL:
Class (Stereo):
CHEMICAL (MIXED)
Sultroponium is an antispasmodic without strong side effects. It is a powerful neurotropic spasmolytic anticholinergic agent.
Status:
Possibly Marketed Outside US
Source:
Xenytropium bromide by Licencia Budapest
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Xenytropium is a quaternary ammonium derivative of atropine. It combines antimuscarinic and ganglionic blocking potencies. It was marketed in Eastern Europe under trade name Gastripon for the treatment of gastritis, gastric and duodenal ulcers, gallstone diseases, and other conditions.
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Trichlorfon (Metrifonate), the organophosphorous cholinesterase inhibitor, O,O-dimethylhydroxy-2,2,2-trichlorethyl-phosphonate, has been used sporadically in the treatment of human schistosomiasis for a decade. It has selective and variable schistosomicidal activity against S. haematobium that results from its partial metabolism to a highly active anti-cholinesterase, dichlorvos. Schistosomal cholinesterase is more susceptible to this metabolite than that of the human host, but transient reductions in both plasma and erythrocyte cholinesterase activity are demonstrable at therapeutic dosage. However, despite early concerns about its potential toxicity, metrifonate is well tolerated and has been used effectively and extensively in large-scale control programmes. Its potential to enhance central nervous system cholinergic neurotransmission led to clinical trials for the treatment of people with Alzheimer's disease (AD).
Status:
US Approved Rx
(2013)
First approved in 1958
Class:
MIXTURE
